Triumeq PD NDC 49702-258

NDC codes

FDA NDC Directory

Product NDC (as listed)49702-258Labeler and product segments. Claims need a package NDC.

Product NDC at billing width49702-0258Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
49702-258-37	49702025837	1 KIT in 1 CARTON (49702-258-37) * 90 TABLET, FILM COATED in 1 BOTTLE (49702-272-59)Marketed from Mar 30, 2022

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Triumeq PD
Generic name (nonproprietary): abacavir sulfate, dolutegravir sodium, lamivudine
Dosage form: Kit
Labeler: ViiV Healthcare Company
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 215413
Marketing start: Mar 30, 2022
Listing expires: Dec 31, 2027
Identifiers: Product ID 49702-258_4018a8c7-db0d-481e-b50a-a469ba32ec4bSPL ID 4018a8c7-db0d-481e-b50a-a469ba32ec4bSPL set ID 2997739a-aa91-42aa-a206-a70e2db7b84fRxCUI 1546888, 1546894, 2598348, 2598352UNII J220T4J9Q2, 1Q1V9V5WYQ, 2T8Q726O95UPC 0349702231139

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

NDC on a medical claim

N449702025837 followed by a unit qualifier and the quantity

Package 49702-0258-37. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jul 8, 2024. This label includes a boxed warning.

Indications (excerpt from the label)

TRIUMEQ and TRIUMEQ PD are indicated for the treatment of HIV-1 infection in adults and in pediatric patients aged at least 3 months and weighing at least 6 kg. Limitations of Use: TRIUMEQ and TRIUMEQ PD alone are not recommended in patients with resistance‑associated integrase substitutions or clinically suspected integrase strand transfer inhibitor (INSTI) resistance because the dose of dolutegravir in TRIUMEQ and TRIUMEQ PD is insufficient in these subpopulations. See full prescribing information for TIVICAY (dolutegravir). TRIUMEQ and TRIUMEQ PD are a combination of dolutegravir (integrase strand transfer inhibitor [INSTI]), abacavir, and lamivudine (both nucleoside analogue reverse tran…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)